#EULAR2019 Emapalumab - a monoclonal Ab against IFNγ - was shown to be effective in 6 systemic JIA (Stills) patients with macrophage activation syndrome. Rx led to rapid neutralization of IFNγ, normalization of CXCL9, & decreased T cell activation. OP0204 https://t.co/9mtxPkHZr3